NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $989,095 | -9.0% | 125,839 | +15.6% | 0.00% | 0.0% |
| Q2 2023 | $1,087,412 | +18.0% | 108,850 | +4.9% | 0.00% | 0.0% |
| Q1 2023 | $921,558 | -21.2% | 103,779 | -2.5% | 0.00% | -33.3% |
| Q4 2022 | $1,169,139 | +32.6% | 106,479 | +57.4% | 0.01% | +20.0% |
| Q3 2022 | $882,000 | +425.0% | 67,655 | +410.0% | 0.01% | +400.0% |
| Q2 2022 | $168,000 | -7.7% | 13,265 | +2.0% | 0.00% | 0.0% |
| Q1 2022 | $182,000 | -51.6% | 13,005 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $376,000 | – | 13,005 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |